19300-54-0Relevant academic research and scientific papers
Intermolecular Palladium-Catalyzed Oxidative Fluorocarbonylation of Unactivated Alkenes: Efficient Access to β-Fluorocarboxylic Esters
Qi, Xiaoxu,Yu, Feng,Chen, Pinhong,Liu, Guosheng
, p. 12692 - 12696 (2017)
A novel palladium-catalyzed intermolecular oxidative fluorocarbonylation of alkenes has been developed, in which employment of a cooperative process with electrophilic ArIF2-meidated alkenes activation and palladium-catalyzed carbonylation is c
Fine-tuning latent fingerprint detection on paper using 1,2-indanedione bi-functional reagents
Lee, Jisun,Joullié, Madeleine M.
, p. 7620 - 7629 (2015)
In order to address the need for consistency and generality in chemical methods developed for detection of latent fingerprints on paper substrates, a practical protocol was developed using 1,2-indanedione-based bi-functional reagents. A series of novel bi
ISOMERIZATION REACTIONS OF LITHIUM N-BUTYL-4-PENTENYLAMIDE
Newcomb, Martin,Burchill, Michael T.
, p. 4867 - 4870 (1982)
Lithium N-butyl-4-pentenylamide (1) in tetrahydrofuran at 22 deg C rearranged smoothly to give a mixture (after protonation) of 1-butyl-2-methylpyrrolidine, formed by an unusual cyclization process, and cis- and trans-N-butyl-pentenylamine; in the presence of 2.0 molar equiv of hexamethylphosphoramide, the total rate of isomerization was accelerated by a factor of 2.5.
Metal-free Photochemical Atom Transfer Radical Addition (ATRA) of BrCCl3 to Alkenes
Nikitas, Nikolaos F.,Voutyritsa, Errika,Gkizis, Petros L.,Kokotos, Christoforos G.
supporting information, p. 96 - 101 (2021/01/04)
A simple, photochemical, and metal-free protocol for the atom transfer radical addition (ATRA) of bromotrichloromethane onto various alkenes is described. Among a range of organic molecules, phenylglyoxylic acid proved to be the most suitable photoinitiator to promote a sustainable process for the addition of bromotrichloromethane to olefins. This photochemical atom transfer radical protocol can be expanded into a wide substrate scope of aliphatic olefins bearing various functional groups, leading to the corresponding products in good to excellent yields.
Highly Regioselective Copper-Catalyzed Transfer Hydrodeuteration of Unactivated Terminal Alkenes
Clark, Joseph R.,Reyes, Albert,Torres, Emanuel Rivera,Vang, Zoua Pa
supporting information, (2022/01/06)
Catalytic transfer hydrodeuteration of unactivated alkenes is challenging because of the requirement that chemically similar hydrogen and deuterium undergo selective insertion across a π-bond. We now report a highly regioselective catalytic transfer hydro
Synthesis and characterization of light-fluorous NHC-ligands and their palladium complexes
Horváth, István T.,Lo, Angel S. W.,Yiu, Ken S. M.
, (2020/12/14)
Light-fluorous ponytails containing perfluoro-n-propyl, perfluoro-n-butyl and perfluoro-t-butoxy groups were used to synthesize light-fluorous α-olefins, branched dialkyl iodides, alkyl triflates, alkyl imidazoles, and dialkyl imidazolium salts. The latte
Mechanistically Guided Design of Ligands That Significantly Improve the Efficiency of CuH-Catalyzed Hydroamination Reactions
Thomas, Andy A.,Speck, Klaus,Kevlishvili, Ilia,Lu, Zhaohong,Liu, Peng,Buchwald, Stephen L.
supporting information, p. 13976 - 13984 (2018/10/25)
Using a mechanically guided ligand design approach, a new ligand (SEGFAST) for the CuH-catalyzed hydroamination reaction of unactivated terminal olefins has been developed, providing a 62-fold rate increase over reactions compared to DTBM-SEGPHOS, the previous optimal ligand. Combining the respective strengths of computational chemistry and experimental kinetic measurements, we were able to quickly identify potential modifications that lead to more effective ligands, thus avoiding synthesizing and testing a large library of ligands. By optimizing the combination of attractive, noncovalent ligand-substrate interactions and the stability of the catalyst under the reaction conditions, we were able to identify a finely tuned hybrid ligand that greatly enables accelerated hydrocupration rates with unactivated alkenes. Moreover, a modular and robust synthetic sequence was devised, which allowed for the practical, gram-scale synthesis of these novel hybrid ligand structures.
Fluorofunctionalization of C=C Bonds with Selectfluor: Synthesis of β-Fluoropiperazines through a Substrate-Guided Reactivity Switch
Capilato, Joseph N.,Bume, Desta Doro,Lee, Wei Hao,Hoffenberg, Louis E. S.,Jokhai, Rayyan Trebonias,Lectka, Thomas
, p. 14234 - 14244 (2019/01/03)
The halofunctionalization of alkene substrates remains an essential tool for synthetic chemists. Herein, we report regioselective ammoniofluorination of unactivated alkenes through photochemical means. A one-pot transformation of the ammonium fluoride products into pharmaceutically relevant β-fluoropiperazines is highlighted. Furthermore, a substrate-guided reactivity switch is observed: certain alkenes are shown to react with the same fluorinating reagent to instead give the less-substituted fluoride. We hope that the ammoniofluorination reaction will be of utility in the area of medicinal chemistry, where nitrogen and fluorine are among the most important heteroatoms.
Exploring physicochemical space: Via a bioisostere of the trifluoromethyl and ethyl groups (BITE): Attenuating lipophilicity in fluorinated analogues of Gilenya for multiple sclerosis
Erdeljac, Nathalie,Kehr, Gerald,Ahlqvist, Marie,Knerr, Laurent,Gilmour, Ryan
supporting information, p. 12002 - 12005 (2018/11/21)
The direct, catalytic vicinal difluorination of terminal alkenes via an I(i)/I(iii) manifold was exploited to install a chiral, hybrid bioisostere of the CF3 and Et groups (BITE) in Gilenya; the first orally available drug for the clinical management of Multiple Sclerosis (MS). This subtle fluorination pattern allows lipophilicity (logD) to be tempered compared to the corresponding CF3 and Et derivatives (CH2CH3 > CH2CF3 > CHFCH2F).
Piperazine derivatives and their use as therapeutic agents
-
Paragraph 0125, (2016/03/19)
Compounds for treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the compounds are of formula (I): where x y, W, V, R 2 , R 3 , R 4 , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , R 8a , R 9 and R 9a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
